Pulmo BioTech Incorporated announced this week that its subsidiary, PulmoScience Incorporated, has completed the bio-distribution studies on its DFH-12 product candidate for the PulmoBind technology of molecular imaging of the lung’s vascular system. The completion of this study is a milestone for the company, proving the success of their molecule, code named DFH-12, and its application in other imaging technologies.

DFH-12 works, via injection, because the molecule is designed to bond only to the inner walls of the vascular system of the lungs. The DFH-12 molecule is tagged with a radionuclide, so the integrity of the lung’s vascular system can be imaged using the gamma cameras present in all hospitals with nuclear medicine imaging departments.

The new molecule’s success was demonstrated in several independent cases that showed the molecule is predominantly retained in the lungs for 30 minutes after injection, with only minor retention (~ 1/10th) in the

Taplmmune, Inc. (TPIM.OB) is a developer of new innovative therapeutics and vaccines in the oncology and infectious disease areas. The company’s therapeutics and vaccines are based on technologies that utilize transporters associated with Antigen Processing (TAP). TAP therapy offers improvements in efficacy as well as reduced side effects and a boost in body defenses.

Teplmmune’s TAP cancer vaccine primarily moves antigens to the surface of cells and restores TAP proteins and the immune system’s ability to recognize and destroy cancer cells. The TAP molecule has also shown abilities to enhance the potency of vaccines against infectious diseases.

Taplmmune’s TAP has already been through clinical studies and has proven several forms of cancer that are deficient to the vaccine. Some cancers deficient to the vaccine include melanoma, colon, cervical, lung, prostate, breast and ovarian. The company began their preclinical testing of TAP in 2007, and is currently